Bo Jesper Hansen

Chairman of the Board

Independent board member since 2009

Nationality: Danish

Age: 53

Mr Hansen has experience in the field of international contract negotiation and deal-making, including execution of high-impact license agreements and significant M&A transactions, international marketing, extensive knowledge of legislative conditions, pharmaco surveillance, medical marketing, business development, and he has many connections within the medical industry and especially within the orphan drug market.

Since 1998 and until mid January 2010, Bo Jesper Hansen was CEO and President of Swedish Orphan International AB.

He has worked for Swedish Orphan International AB since 1993, has established subsidiaries in Norway and Denmark and is furthermore responsible for the current expansion in Europe.

Bo Jesper Hansen was employed in various positions in Swedish Orphan International until he became Vice President in the parent company and later on was appointed CEO of the company.

In this period, he moreover co-founded the Prostate Clinic in Denmark.

Before joining Swedish Orphan International AB, Bo Jesper Hansen worked as medical advisor for a number of the large medical companies through his privately held company, Scandinavian Medical Research.

Today, he is Chairman of the Board at Swedish Orphan Biovitrum AB (publ) and board member at MipSalus ApS, Zymenex A/S, Gambro AB, Orphazyme ApS, Novagali Pharma S.A., and CMC Kontrast AB, Hyperion Therapeutics Inc., and Genspera Inc.

Bo Jesper Hansen is an MD, has a PhD from the University of Copenhagen, and is the author of more than 40 publications.